Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

NBOMe — a very different kettle of fish . . .

To the Editor: We are concerned that recent media reports about a 17-year-old Sydney boy who died after allegedly consuming 25B- or 25I-NBOMe might lead to an increase in the incidence of NBOMe toxicity among patients presenting to emergency departments. NBOMe was reported to be available online for as little as $1.50 per tablet.1 The subsequent media interest is likely to have increased public awareness of the availability of the NBOMe series of drugs; and increased awareness of psychoactive substances through media reporting is associated with their increased initial uptake.2 It is possible that the increased awareness of this cheap LSD (lysergic acid diethylamide)-like drug will prompt some individuals to buy NBOMe tablets and sell them as LSD in order to make a significant profit.

The NBOMe series are analogues of the 2C series of psychedelic phenethylamine drugs that include an N-methoxybenzyl (hence, “NBOMe”) substituent that has significant effects on their pharmacological activity. NBOMe drugs have been characterised in in-vitro receptor studies as remarkably potent agonists of the 5-HT2A and 5-HT2C receptors,